At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 208 enrolled
Drug / intervention
elezanumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Relapsing Forms of Multiple Sclerosis
In Brief
A Phase 2 clinical trial evaluating elezanumab and placebo for Multiple Sclerosis (MS). Completed, enrolled 208 participants across 49 sites in 2 countries.
Detailed Summary
The purpose of this study is to evaluate the safety and efficacy of elezanumab in participants with relapsing Multiple Sclerosis (RMS).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Sclerosis (MS)
CountriesCanada, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedNov 2018
Enrollment StartDec 2018
Primary CompletionAug 2021
Study CompletionSep 2021
TodayJul 2026
First PostedNov 13, 2018
Enrollment StartDec 11, 2018
Primary CompletionAug 9, 2021
Study CompletionSep 9, 2021
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 7.6 years ago
Interventions
elezanumabdrug
solution for infusion
placebodrug
solution for infusion